IO Biotech Shares Face Mounting Pressure After Regulatory Setback

IO Biotech’s stock continues its downward trajectory, with Monday’s 12 percent plunge signaling further volatility ahead. The company confronts a challenging landscape defined by regulatory hurdles and a significant corporate restructuring initiative.

Restructuring and Financial Strain

In response to recent developments, IO Biotech is implementing a workforce reduction that will eliminate half of its positions. This restructuring is projected to cost the company between $1.0 million and $1.5 million, with the stated goal of extending its financial runway only through the first quarter of 2026.

The company’s financial position shows considerable strain. Despite reporting $28.1 million in liquid assets and securing an additional €12.5 million credit facility in July 2025, IO Biotech continues to burn through cash rapidly. The second quarter of 2025 saw net losses widen to $26.2 million, compared to $20.7 million during the same period last year.

Regulatory Hurdles Delay Cancer Vaccine

The primary catalyst behind the negative sentiment stems from a significant regulatory setback with the U.S. Food and Drug Administration. The agency advised against submitting a marketing application for IO Biotech’s cancer vaccine candidate, Cylembio, despite encouraging Phase 3 trial results. While the combination therapy with Merck’s pembrolizumab demonstrated clinically meaningful survival benefits, it narrowly missed statistical significance requirements, with a p-value of 0.0558 versus the required p≤0.045.

Should investors sell immediately? Or is it worth buying IO Biotech?

This regulatory guidance represents a substantial blow to the company’s timeline. Instead of the originally anticipated 2026 market launch, Cylembio may not reach commercialization until 2029. The delay stems from the necessity to design and execute an entirely new registration study—a process that will be both time-consuming and costly.

Market Reaction and Technical Outlook

Financial institutions have responded decisively to these developments. Morgan Stanley reduced its price target from $6.00 to $4.00, though it maintained its overweight rating. Other firms including TD Cowen and H.C. Wainwright took more aggressive action, downgrading their ratings entirely.

Technical indicators currently flash clear sell signals across both short-term and long-term moving averages. The critical question facing investors is whether IO Biotech can sustain operations long enough to conduct its next registration trial, or if the company faces an existential threat.